Taking into account these inherent limitations, our findings suggest that risk stratification based on clinical-pathological factors, such as tumor grade, Ki67, ER, and PgR, could be useful in personalizing treatment according to patient menopausal status. The gene discussed is ESR1; the disease is neoplasm.